|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang WR, Fang JY, Wu KS, Shi XJ, Luo JY
and Lin K: Epidemiological characteristics and prediction of
esophageal cancer mortality in China from 1991 to 2012. Asian Pac J
Cancer Prev. 15:6929–6934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song QK, Li J, Jiang HD, He YM, Zhou XQ
and Huang CY: Esophageal cancer mortality during 2004–2009 in
Yanting County, China. Asian Pac J Cancer Prev. 13:5003–5006. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu Y, Yu X, Chen Q and Mao W: Neoadjuvant
versus adjuvant treatment: which one is better for resectable
esophageal squamous cell carcinoma? World J Surg Oncol. 10:1732012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blot WJ: Esophageal cancer trends and risk
factors. Semin Oncol. 21:403–410. 1994.PubMed/NCBI
|
|
6
|
Brooks-Brunn JA: Esophageal cancer: an
overview. Medsurg Nurs. 9:248–254. 2000.PubMed/NCBI
|
|
7
|
Scripture CD, Figg WD and Sparreboom A:
Paclitaxel chemotherapy: from empiricism to a mechanism-based
formulation strategy. Ther Clin Risk Manag. 1:107–114. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ajani JA, Ilson DH, Daugherty K, Pazdur R,
Lynch PM and Kelsen DP: Activity of taxol in patients with squamous
cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer
Inst. 86:1086–1091. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ilson DH, Ajani J, Bhalla K, Forastiere A,
Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, et al:
Phase II trial of paclitaxel, fluorouracil, and cisplatin in
patients with advanced carcinoma of the esophagus. J Clin Oncol.
16:1826–1834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adelstein DJ, Rice TW, Rybicki LA, Larto
MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA and Zuccaro G:
Does paclitaxel improve the chemoradiotherapy of locoregionally
advanced esophageal cancer? A nonrandomized comparison with
fluorouracil-based therapy. J Clin Oncol. 18:2032–2039. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polee MB, Eskens FA, van der Burg ME,
Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G and van
der Gaast A: Phase II study of bi-weekly administration of
paclitaxel and cisplatin in patients with advanced oesophageal
cancer. Br J Cancer. 86:669–673. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tishler RB, Schiff PB, Geard CR and Hall
EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol
Phys. 22:613–617. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choy H, Rodriguez FF, Koester S,
Hilsenbeck S and Von Hoff DD: Investigation of taxol as a potential
radiation sensitizer. Cancer. 71:3774–3778. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leonard CE, Chan DC, Chou TC, Kumar R and
Bunn PA: Paclitaxel enhances in vitro radiosensitivity of squamous
carcinoma cell lines of the head and neck. Cancer Res.
56:5198–5204. 1996.PubMed/NCBI
|
|
15
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L,
Fernández-Luna JL, Nuñez G, et al: constitutive activation of Stat3
signaling confers resistance to apoptosis in human U266 myeloma
cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukada T, Hibi M, Yamanaka Y,
Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, Nakajima K and Hirano
T: Two signals are necessary for cell proliferation induced by a
cytokine receptor gp130: involvement of STAT3 in anti-apoptosis.
Immunity. 5:449–460. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan S, Zhou C, Zhang W, Zhang G, Zhao X,
Yang S, Wang Y, Lu N, Zhu H and Xu N: Beta-catenin/TCF pathway
upregulates STAT3 expression in human esophageal squamous cell
carcinoma. Cancer Lett. 271:85–97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wegrzyn J, Potla R, Chwae YJ, Sepuri NB,
Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, et
al: Function of mitochondrial Stat3 in cellular respiration.
Science. 323:793–797. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gough DJ, Corlett A, Schlessinger K,
Wegrzyn J, Larner AC and Levy DE: Mitochondrial STAT3 supports
Ras-dependent oncogenic transformation. Science. 324:1713–1716.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blajeski AL, Kottke TJ and Kaufmann SH: A
multistep model for paclitaxel-induced apoptosis in human breast
cancer cell lines. Exp Cell Res. 270:277–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ofir R, Seidman R, Rabinski T, Krup M,
Yavelsky V, Weinstein Y and Wolfson M: Taxol-induced apoptosis in
human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3
and caspase-9 independent. Cell Death Differ. 9:636–642. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varbiro G, Veres B, Gallyas F Jr and
Sumegi B: Direct effect of Taxol on free radical formation and
mitochondrial permeability transition. Free Radic Biol Med.
31:548–558. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Kim CN, Yang J, Jemmerson R and
Wang X: Induction of apoptotic program in cell-free extracts:
requirement for dATP and cytochrome c. Cell. 86:147–157.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Susin SA, Lorenzo HK, Zamzami N, Marzo I,
Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler
M, et al: Molecular characterization of mitochondrial
apoptosis-inducing factor. Nature. 397:441–446. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johnson TM, Yu ZX, Ferrans VJ, Lowenstein
RA and Finkel T: Reactive oxygen species are downstream mediators
of p53-dependent apoptosis. Proc Natl Acad Sci USA. 93:11848–11852.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai J and Jones DP: Mitochondrial redox
signaling during apoptosis. J Bioenerg Biomembr. 31:327–334. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akgul C, Moulding DA and Edwards SW:
Molecular control of neutrophil apoptosis. FEBS Lett. 487:318–322.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zouein FA, Duhé RJ, Arany I, Shirey K,
Hosler JP, Liu H, Saad I, Kurdi M and Booz GW: Loss of STAT3 in
mouse embryonic fibroblasts reveals its janus-like actions on
mitochondrial function and cell viability. Cytokine. 66:7–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carbognin E, Betto RM, Soriano ME, Smith
AG and Martello G: Stat3 promotes mitochondrial transcription and
oxidative respiration during maintenance and induction of naive
pluripotency. EMBO J. 35:618–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boengler K, Hilfiker-Kleiner D, Heusch G
and Schulz R: Inhibition of permeability transition pore opening by
mitochondrial STAT3 and its role in myocardial
ischemia/reperfusion. Basic Res Cardiol. 105:771–785. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nguyen AV, Wu YY, Liu Q, Wang D, Nguyen S,
Loh R, Pang J, Friedman K, Orlofsky A, Augenlicht L, et al: STAT3
in epithelial cells regulates inflammation and tumor progression to
malignant state in colon. Neoplasia. 15:998–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Haricharan S and Li Y: STAT signaling in
mammary gland differentiation, cell survival and tumorigenesis. Mol
Cell Endocrinol. 382:560–569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi(m)) in apoptosis; an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
